Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IV buprenorphine/naloxone challenge study in opioid-dependent subjects stabilized on Suboxone
2011-002229-23Phase 2Completed
- Sponsor
- Indivior
- Start
- May 2012
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of Suboxone, buprenorphine, naloxone and diamorphine in opioid use disorder (OUD), sponsored by Indivior. Primary endpoint: Mean change in Clinical Opiate Withdrawal Scale over 60 minutes post-challenge. Started May 2012; status: completed.
02
Drugs
Suboxonebuprenorphinenaloxonediamorphine
03
Conditions
opioid use disorder (OUD)
Beyond the preview
Go deeper on 2011-002229-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-002229-23.